Kingworld Medicines Group Ltd
HKEX:1110
Intrinsic Value
Kingworld Medicines Group Ltd. is an investment company, which engages in the distribution of imported branded pharmaceutical and healthcare products. [ Read More ]
The intrinsic value of one
Kingworld Medicines Group Ltd
stock under the Base Case scenario is
1.48
HKD.
Compared to the current market price of 0.56 HKD,
Kingworld Medicines Group Ltd
is
Undervalued by 62%.
Kingworld Medicines Group Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Kingworld Medicines Group Ltd's market capitalization is 348.6m HKD.
Kingworld Medicines Group Ltd stock price is 0.56 HKD.
Kingworld Medicines Group Ltd stock price (0.56 HKD) is 62% less than its Intrinsic Value (1.48 HKD).
Kingworld Medicines Group Ltd stock price (0.56 HKD) is 59% less than its DCF Value (1.36 HKD). Open DCF Valuation
Kingworld Medicines Group Ltd stock price (0.56 HKD) is 65% less than its Relative Value (1.59 HKD). Open Relative Valuation
Kingworld Medicines Group Ltd has upside potential of 223% compared to the average analyst price target.
Open Wall St Estimates
Kingworld Medicines Group Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 5% to 6%.
Kingworld Medicines Group Ltd has positive Net Debt. This means that the company has more debt (348m CNY) than cash and short-term investments (194m CNY).
Kingworld Medicines Group Ltd has positive Operating Income for the last twelve months.
Kingworld Medicines Group Ltd's Revenue has grown by 13% over the past 12 months.
Kingworld Medicines Group Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 6%.
Kingworld Medicines Group Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 6%.
Kingworld Medicines Group Ltd's ROE (Return on Equity) has increased in the last 3 years from 2% to 6%.
Kingworld Medicines Group Ltd's short-term assets (589m CNY) exceed its short-term liabilties (464m CNY).
Kingworld Medicines Group Ltd has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
Kingworld Medicines Group Ltd has positive Net Income for the last twelve months.
Kingworld Medicines Group Ltd's Revenue has been growing by 13% per year for the last 3 years.
Kingworld Medicines Group Ltd has a very low three-year average ROE (Return on Equity): 4%. The company is not efficient at transforming stockholders' equity into net income.
Kingworld Medicines Group Ltd has positive Gross Profit for the last twelve months.
Kingworld Medicines Group Ltd's Altman Z-Score is equal to 2.05.
Kingworld Medicines Group Ltd's long-term assets (1B CNY) exceed its long-term liabilties (719m CNY).
Kingworld Medicines Group Ltd has positive Free Cash Flow for the last twelve months.
Kingworld Medicines Group Ltd's D/E (Debt to Equity) is very low and is equal to 0.56.
Valuation Backtest
Kingworld Medicines Group Ltd
Run backtest to discover the historical profit from buying and selling
Kingworld Medicines Group Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Kingworld Medicines Group Ltd
Balance Sheet Decomposition
Kingworld Medicines Group Ltd
| Current Assets | 588.6m |
| Cash & Short-Term Investments | 194m |
| Receivables | 277m |
| Other Current Assets | 117.6m |
| Non-Current Assets | 749m |
| Long-Term Investments | 272.6m |
| PP&E | 385.7m |
| Intangibles | 90.7m |
| Current Liabilities | 463.5m |
| Accounts Payable | 193m |
| Short-Term Debt | 191.7m |
| Other Current Liabilities | 78.9m |
| Non-Current Liabilities | 255.1m |
| Long-Term Debt | 156.4m |
| Other Non-Current Liabilities | 98.7m |
Earnings Waterfall
Kingworld Medicines Group Ltd
|
Revenue
|
1.1B
CNY
|
|
Cost of Revenue
|
-798m
CNY
|
|
Gross Profit
|
280.7m
CNY
|
|
Operating Expenses
|
-195.4m
CNY
|
|
Operating Income
|
85.2m
CNY
|
|
Other Expenses
|
-47.1m
CNY
|
|
Net Income
|
38.1m
CNY
|
Free Cash Flow Analysis
Kingworld Medicines Group Ltd
Profitability Score
Profitability Due Diligence
Kingworld Medicines Group Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Kingworld Medicines Group Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Kingworld Medicines Group Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Kingworld Medicines Group Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Kingworld Medicines Group Ltd
According to Wall Street analysts, the average 1-year price target for
Kingworld Medicines Group Ltd
is 1.81 HKD
.
Shareholder Return
Price
Kingworld Medicines Group Ltd
| Average Annual Return | 7.99% |
| Standard Deviation of Annual Returns | 20.95% |
| Max Drawdown | -61% |
| Market Capitalization | 348.6m HKD |
| Shares Outstanding | 592 452 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Kingworld Medicines Group Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Kingworld Medicines Group Ltd. is an investment company, which engages in the distribution of imported branded pharmaceutical and healthcare products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2010-11-25. The Company’s products include cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza and others. The firm operates through two business segments. The Distribution Sales of Pharmaceutical and Healthcare Products segment is engaged in the distribution and sales of branded imported pharmaceutical and healthcare products primarily in Hong Kong and the People’s Republic of China (PRC). The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment is engaged in the manufacture and sales of electrotherapeutic and physiotherapeutic devices, as well as general medical examination devices in the PRC.
Contact
IPO
Employees
Officers
The intrinsic value of one
Kingworld Medicines Group Ltd
stock under the Base Case scenario is
1.48
HKD.
Compared to the current market price of 0.56 HKD,
Kingworld Medicines Group Ltd
is
Undervalued by 62%.
You don't have any saved screeners yet
